# Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer

> **NCT03462342** · PHASE2 · COMPLETED · sponsor: **University of Pennsylvania** · enrollment: 123 (actual)

## Conditions studied

- High Grade Serous Carcinoma

## Interventions

- **DRUG:** Olaparib Pill
- **DRUG:** AZD6738

## Key facts

- **NCT ID:** NCT03462342
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-09
- **Primary completion:** 2025-07-21
- **Final completion:** 2025-07-21
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2026-04-13

## Collaborators

- AstraZeneca

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03462342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03462342, "Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03462342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*